Drug Name: Opdualag
Active Ingredient: nivolumab and relatlimab-rmbw
Indications: To treat unresectable or metastatic melanoma
Approval Date: 3/18/2022
Company: Bristol-Myers Squibb Company
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf